3 stories mentioning CAIUpdated 25d ago
Every FINWIRES story that references CAI, newest first.
Caris Life Sciences, Inc. (CAI) has an average rating of overweight and mean price target of $27.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $17.20, Change: $+0.21, Percent Change: +1.21%
Jeff L Vacirca, Director, on May 11, 2026, executed a purchase for 31,050 shares in Caris Life Sciences (CAI) for $501,426. Following the Form 4 filing with the SEC, Vacirca has control over a total of 49,671 common shares of the company, with 49,671 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2019410/000172416126000005/xslF345X05/wk-form4_1778588549.xml
Caris Life Sciences (CAI) has an average rating of buy and mean price target of $30.79, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
